Investigates RPE and ROCK involvement in subretinal fibrosis in neovascular AMD, suggesting new therapeutic targets.
Purpose: To investigate the cellular origin and molecular mechanisms underlying subretinal fibrosis (SRF) in neovascular AMD (nAMD), with a focus on the role of RPE and Rho-associated coiled-coil-containing protein kinase (ROCK)–mediated epithelial-mesenchymal transition (EMT). Methods: Fate-mapping with lineage tracing, laser capture microdissection, microarray and RT-PCR analyses, immunohistochemistry, and functional assays with ROCK inhibitors (Ripasudil, Belumosudil) were used to assess EMT/endothelial-to-mesenchymal transition contributions to SRF and ROCK pathway involvement. Results: Fate mapping identified RPE and endothelial cells as sources of myofibroblasts. EMT-related gene upregulation and ROCK1/2 expression were observed in SRF lesions. RPE-specific ROCK2 knockout significantly reduced fibrosis and EMT markers. Ripasudil suppressed SRF development and reversed EMT both in vivo and in vitro. ROCK expression was confirmed in human choroidal neovascularization membranes. Conclusions: RPE-derived myofibroblasts via ROCK2-mediated EMT play a dominant role in SRF formation. ROCK inhibitors, particularly Ripasudil, may serve as effective therapeutic agents against fibrosis in nAMD.
No takes yet. Share an insight, caveat, or question.
Wada et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: